These results suggest that additional genetic alterations in cancer cells that occur in the course of tumor progression (e.g., overexpression of CITED2 and/or loss of RKIP gene) induce de novo chemokines (e.g., CCL20 and/or CCL5) that recruit TAMs to primary tumor sites (Figure 2B). This evidence concerns the gene CITED2 and neoplasm.